Baseline characteristics
Characteristics | |
Overall cases | 23 470 |
Age, median (IQR) | 40 (30–54) |
Sex, N (%) | |
Male | 11 008 (46.9) |
Female | 12 462 (53.1) |
Date of treatment, N (%) | |
2017 | 3957 (16.9) |
2018 | 6486 (27.6) |
2019 | 7568 (32.2) |
2020 | 5459 (23.3) |
Season, N (%) | |
Spring | 4473 (19.1) |
Summer | 5942 (25.3) |
Autumn | 6322 (26.9) |
Winter | 6733 (28.7) |
Antibiotic regimens, N (%) | |
Amoxicillin+furazolidone | 16 784 (71.5) |
Amoxicillin+clarithromycin | 4182 (17.8) |
Amoxicillin+levofloxacin | 309 (1.3) |
Furazolidone+clarithromycin | 1669 (7.1) |
Furazolidone+levofloxacin | 358 (1.5) |
Clarithromycin+levofloxacin | 95 (0.4) |
Others | 73 (0.3) |
Duration, N (%) | |
10 | 5641 (24.0) |
12 | 1060 (4.5) |
14 | 16 769 (71.4) |
Proton pump inhibitor, N (%) | |
Rabeprazole10mg | 9654 (41.1) |
Rabeprazole20mg | 21 (0.1) |
Pantoprazole | 5815 (24.8) |
Esomeprazole | 4811 (20.5) |
Omeprazole | 2236 (9.5) |
Lansoprazole | 933 (4.0) |